Lexaria Bioscience (NASDAQ:LEXX) & Siga Technologies (NASDAQ:SIGA) Head-To-Head Review

Siga Technologies (NASDAQ:SIGA) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Risk & Volatility

Siga Technologies has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Valuation and Earnings

This table compares Siga Technologies and Lexaria Bioscience”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57 million	2.49	$23.28 million	($0.05)	-65.60
Lexaria Bioscience	$710,000.00	9.51	-$11.90 million	($5.10)	-0.63

Siga Technologies has higher revenue and earnings than Lexaria Bioscience. Siga Technologies is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 2.7% of Siga Technologies shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Siga Technologies and Lexaria Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1	0	0	0	1.00
Lexaria Bioscience	1	0	1	0	2.00

Lexaria Bioscience has a consensus price target of $22.50, indicating a potential upside of 603.12%. Given Lexaria Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Siga Technologies.

Profitability

This table compares Siga Technologies and Lexaria Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Lexaria Bioscience	N/A	-174.93%	-143.89%

About Siga Technologies

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.